Abstract
Background
Hypertrophic cardiomyopathy (HCM) is a serious disorder and one of the leading causes of mortality worldwide. HCM is characterized as left ventricular hypertrophy in the absence of any other loading conditions. In previous studies, mutations in at least 50 genes have been identified in HCM patients.
Methods
In this research, the genetic lesion of an HCM patient was identified by whole exome sequencing. Real-time polymerase chain reaction (PCR), immunofluorescence and Western blot were used to analyze the effects of the identified mutation.
Results
According to whole exome sequencing, we identified a de novo mutation (c.814T>C/p.F272L) of SET and MYND domain containing histone methyltransferase 1 (SMYD1) in a Chinese patient with HCM exhibiting syncope. We then generated HIS-SMYD1-pcDNA3.1+ (WT and c.814T>C/p.F272L) plasmids for transfection into AC16 cells to functionalize the mutation. The immunofluorescence experiments indicated that this mutation may block the SMYD1 protein from entering the nucleus. Both Western blot and real-time PCR revealed that, compared with cells transfected with WT plasmids, the expression of HCM-associated genes such as β-myosin heavy chains, SMYD1 chaperones (HSP90) and downstream targets including TGF-β were all disrupted in cells transfected with the mutant plasmid. Previous studies have demonstrated that SMYD1 plays a crucial role in sarcomere organization and heart development.
Conclusions
This novel mutation (c.814T>C/p.F272L) may be the first identified disease-causing mutation of SMYD1 in HCM patients worldwide. Our research expands the spectrum of HCM-causing genes and contributes to genetic counseling for HCM patients.
Acknowledgments
We thank all subjects for participating in this study.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This study was supported by the National Natural Science Foundation of China (81370394 and 81500359).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017;121:749–70.10.1161/CIRCRESAHA.117.311059Search in Google Scholar PubMed PubMed Central
2. Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mechanistic insights into the genetics of cardiomyopathy. J Am Coll Cardiol 2016;68:2871–86.10.1016/j.jacc.2016.08.079Search in Google Scholar PubMed PubMed Central
3. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 2013;381:242–55.10.1016/S0140-6736(12)60397-3Search in Google Scholar PubMed
4. Sabater-Molina M, Perez-Sanchez I, Hernandez Del Rincon JP, Gimeno JR. Genetics of hypertrophic cardiomyopathy: a review of current state. Clin Genet 2018;93:3–14.10.1111/cge.13027Search in Google Scholar PubMed
5. Nagandla H, Lopez S, Yu W, Rasmussen TL, Tucker HO, Schwartz RJ, et al. Defective myogenesis in the absence of the muscle-specific lysine methyltransferase SMYD1. Dev Biol 2016;410:86–97.10.1016/j.ydbio.2015.12.005Search in Google Scholar PubMed
6. Stewart MD, Lopez S, Nagandla H, Soibam B, Benham A, Nguyen J, et al. Mouse myofibers lacking the SMYD1 methyltransferase are susceptible to atrophy, internalization of nuclei and myofibrillar disarray. Dis Model Mech 2016;9:347–59.10.1242/dmm.022491Search in Google Scholar PubMed PubMed Central
7. Franklin S, Kimball T, Rasmussen TL, Rosa-Garrido M, Chen H, Tran T, et al. The chromatin-binding protein Smyd1 restricts adult mammalian heart growth. Am J Physiol Heart Circ Physiol 2016;311:H1234–47.10.1152/ajpheart.00235.2016Search in Google Scholar PubMed PubMed Central
8. Liu JS, Fan LL, Li JJ, Xiang R. Whole-exome sequencing identifies a novel mutation of desmocollin 2 in a Chinese family with arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2017;119:1485–9.10.1016/j.amjcard.2017.01.011Search in Google Scholar PubMed
9. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 2014;11:361–2.10.1038/nmeth.2890Search in Google Scholar PubMed
10. Consortium GT. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013;45:580–5.10.1038/ng.2653Search in Google Scholar PubMed PubMed Central
11. Kaimal V, Bardes EE, Tabar SC, Jegga AG, Aronow BJ. ToppCluster: a multiple gene list feature analyzer for comparative enrichment clustering and network-based dissection of biological systems. Nucleic Acids Res 2010;38:W96–102.10.1093/nar/gkq418Search in Google Scholar PubMed PubMed Central
12. Xiang R, Fan LL, Lin MJ, Li JJ, Shi XY, Jin JY, et al. The genetic spectrum of familial hypercholesterolemia in the central south region of China. Atherosclerosis 2017;258:84–8.10.1016/j.atherosclerosis.2017.02.007Search in Google Scholar PubMed
13. Kosugi S, Hasebe M, Tomita M, Yanagawa H. Systematic identification of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of composite motifs. Proc Natl Acad Sci USA 2009;106:10171–6.10.1073/pnas.0900604106Search in Google Scholar PubMed PubMed Central
14. Rasmussen TL, Ma Y, Park CY, Harriss J, Pierce SA, Dekker JD, et al. Smyd1 facilitates heart development by antagonizing oxidative and ER stress responses. PLoS One 2015;10:e0121765.10.1371/journal.pone.0121765Search in Google Scholar PubMed PubMed Central
15. Tan X, Rotllant J, Li H, De Deyne P, Du SJ. SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos. Proc Natl Acad Sci USA 2006;103:2713–8.10.1073/pnas.0509503103Search in Google Scholar PubMed PubMed Central
16. Li D, Niu Z, Yu W, Qian Y, Wang Q, Li Q, et al. SMYD1, the myogenic activator, is a direct target of serum response factor and myogenin. Nucleic Acids Res 2009;37:7059–71.10.1093/nar/gkp773Search in Google Scholar PubMed PubMed Central
17. Just S, Meder B, Berger IM, Etard C, Trano N, Patzel E, et al. The myosin-interacting protein SMYD1 is essential for sarcomere organization. J Cell Sci 2011;124:3127–36.10.1242/jcs.084772Search in Google Scholar PubMed
18. Abaci N, Gulec C, Bayrak F, Komurcu Bayrak E, Kahveci G, Erginel Unaltuna N. The variations of BOP gene in hypertrophic cardiomyopathy. Anadolu Kardiyol Derg 2010;10:303–9.10.5152/akd.2010.087Search in Google Scholar PubMed
19. Park CY, Pierce SA, von Drehle M, Ivey KN, Morgan JA, Blau HM, et al. skNAC, a Smyd1-interacting transcription factor, is involved in cardiac development and skeletal muscle growth and regeneration. Proc Natl Acad Sci USA 2010;107:20750–5.10.1073/pnas.1013493107Search in Google Scholar PubMed PubMed Central
20. Liu G, Ding W, Neiman J, Mulder KM. Requirement of Smad3 and CREB-1 in mediating transforming growth factor-beta (TGF beta) induction of TGF beta 3 secretion. J Biol Chem 2006;281:29479–90.10.1074/jbc.M600579200Search in Google Scholar PubMed
21. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 2014;64:83–99.10.1016/j.jacc.2014.05.003Search in Google Scholar PubMed
Supplementary Material
The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2018-0578).
©2019 Walter de Gruyter GmbH, Berlin/Boston
